Carveol

SKU: orb1297116

Description

(-)-Carveol is a monocyclic monoterpenoid alcohol found in essential oils like Cymbopogon giganteus and spices such as caraway. Research applications include its study in antimicrobial, antioxidant, and anti-inflammatory assays, utilizing both in vitro and in vivo experimental models.

Research Area

Metabolism Research

Key Properties

• CAS Number: 99-48-9
• MW: 152.23
• Purity: 98.61%
• Formula: C₁₀H₁₆O
• SMILES: CC(=C)C1CC=C(C)C(O)C1
• Target: Endogenous Metabolite
• Solubility: DMSO:50 mg/mL (328.45 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (13.14 mM)

Bioactivity

• In Vivo:
  (-)-Carveol has low toxicity, with a lethal dose 50% (LD50) equal to or greater than 2,500 mg/kg according to OECD guide no 423. In all gastric ulcer induction methods evaluated, (-)-Carveol (25, 50, 100 and 200 mg/kg, p.o.) significantly reduced the ulcerative lesion in comparison with the respective control groups. In the experimental protocol of pylorus ligation-induced gastric ulcer, (-)-Carveol (100 mg/kg) reduced (p < 0.001) the volume of gastric secretion in both routes (oral and intraduodenal). The previous administration of blockers NEM (sulfhydryl groups blocker), L-NAME (nitric oxide synthesis inhibitor), glibenclamide (KATP channel blocker) and indomethacin (cyclo-oxygenase inhibitor), significantly reduced the gastroprotection exercised by (-)-Carveol, suggesting the participation of these pathways in its gastroprotective activity. In addition, treatment with (-)-Carveol (100 mg/kg) increased (p < 0.001) mucus adhered to the gastric wall. Treatment also increased (p < 0.001) levels of reduced glutathione (GSH), superoxide dismutase (SOD) and interleukin-10 (IL-10). It also reduced (p < 0.001) malondialdehyde (MDA), myeloperoxidase (MPO), interleukin-1 beta (IL-1β) and tumor necrosis factor-alpha (TNF-α) levels.
• In Vitro:
  (-)-Carveol exhibited a significant vasorelaxant effect on KCl and 5-HT-induced contractions, obtaining EC50 values of 344.25 ± 8.4 and 175.82 ± 4.05 μM, respectively. The participation of calcium channels in the relaxation produced by (-)-carveol was analyzed using vessels pre-incubated with (-)-carveol (2000 μM) in a calcium-free medium, where the induction of contractions was abolished. The vasorelaxant effect of (-)-carveol on HUAs was reduced by tetraethylammonium (TEA), which increased the (-)-carveol EC50 to 484.87 ± 6.55 μM. The present study revealed that (-)-carveol possesses a vasorelaxant activity in HUAs, which was dependent on the opening of calcium and potassium channels.

Storage & Handling

• Storage: Pure form: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Carveol, Carveol, mixture of isomers, Human Endogenous Metabolite, EndogenousMetabolite, Endogenous Metabolite

Compound Identifiers

PubChem CID

7438